Welcome to our dedicated page for VRAY news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on VRAY stock.
ViewRay, Inc. (Nasdaq: VRAY) pioneers MRI-guided adaptive radiotherapy through its MRIdian® system, which enhances cancer treatment precision with real-time imaging and adaptive dosing. This page aggregates official announcements, financial updates, and clinical milestones for investors and healthcare professionals tracking advancements in radiation therapy technology.
Key resources include: Press releases on MRIdian® installations like the VA Oklahoma City partnership, earnings reports, regulatory clearances, and research collaborations. Stay informed on ViewRay's role in expanding access to non-invasive therapies that prioritize patient safety and outcomes.
Bookmark this page for streamlined access to verified updates about VRAY's innovations in medical technology. Visit regularly to monitor developments in MRI-guided treatment adoption and ViewRay's global impact on oncology care.
ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023. Domestic callers can join at (888) 886-7786 using confirmation number 56031524. A live webcast will also be available on ViewRay's investor relations page. The MRIdian® MR-Guided Radiation Therapy System, designed with high-definition MR imaging, addresses challenges in advanced radiation oncology, such as beam distortion and skin toxicity. This innovative technology differentiates itself from conventional MR systems used in diagnostic radiology.
ViewRay (NASDAQ: VRAY) announced that the Czech Ministry of Health has approved the acquisition of its MRIdian system, making it the first and only facility to provide advanced MRI-guided radiation therapy in the Czech Republic at the Military University Hospital Prague. This purchase, partially funded by the REACT-EU financial instrument, enhances cancer treatment options with precision technology that includes real-time tissue tracking and automatic beam control. Over 29,000 patients have already benefited from MRIdian systems, which are installed in 57 hospitals worldwide.
